Advances in 3D Bioprinting for Breast Cancer Modeling: Tumor Microenvironment, Metastasis, and Drug Screening
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.71734 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Mustafa Nakipoglu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Genetics, Faculty of Sciences, Bartın University, Bartın, Turkiye. Hauptthemen laut MEDLINE: Tumor Microenvironment, Breast Neoplasms, Bioprinting, Printing, Three-Dimensional. Die Arbeit nennt 208 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, American Heart Association, Estonian Research Council.
Abstract (Originalsprache)
The tumor microenvironment (TME) is a complex and heterogeneous milieu encompassing biological and biochemical events and diverse physical, chemical, and mechanical interactions between tumor and stromal cells. This heterogeneity plays a pivotal role in regulating tumor progression, metastasis, and resistance to therapy. In breast cancer, cancer‐associated fibroblasts, adipocytes, endothelial cells, and immune cells all contribute to this intricate environment, necessitating precise spatial and cellular modeling to better replicate physiological conditions. Moreover, angiogenesis and metastasis are key contributors to breast cancer mortality. Therefore, three‐dimensional (3D) models that incorporate co‐cultures of cancer and stromal cells are essential for recreating realistic TMEs. This review highlights the advances in 3D bioprinting technologies for modeling the breast cancer TME. We discuss their potential in drug screening, explore their advantages and limitations, and outline future directions to enhance their fidelity and translational relevance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Biology and Genetics, Faculty of Sciences, Bartın University, Bartın, Turkiye.
- Department of Bioengineering, Samueli School of Engineering, University of California, Los Angeles, California, USA.
- Department of Biomedical Engineering, Ya. C., Islamic Azad University, Yazd, Iran.
- Joint Reconstruction Research Center, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Biomedical Sciences, Northeast Ohio Medical University, Rootstown, Ohio, USA.
- 3D Tissue Bioprinting Laboratory, Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), National Institute of Health (NIH), Rockville, MD, USA.
ORCID-Profile: Mustafa Nakipoglu, Mahboobeh Mahmoodi, Ehsanul Hoque Apu, Halima Alem
Förderung
- NIH HHS
- American Heart Association
- Estonian Research Council
- Michigan Translational Research and Commercialization Innovation Hub for AgBio
- Henry Ford Health, Department of Surgery
- Corewell Health and Michigan State University Alliance
- National Institutes of Health
- Eesti Teadusagentuur
Zitieren
APA
Nakipoglu, M., Mahmoodi, M., Apu, E. H., Shahabipour, F., Emir Diltemiz, S., Saha, S., Alem, H., & Ashammakhi, N. (2026). Advances in 3D Bioprinting for Breast Cancer Modeling: Tumor Microenvironment, Metastasis, and Drug Screening. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71734
Vancouver
Nakipoglu M, Mahmoodi M, Apu EH, Shahabipour F, Emir Diltemiz S, Saha S, et al. Advances in 3D Bioprinting for Breast Cancer Modeling: Tumor Microenvironment, Metastasis, and Drug Screening. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.71734
BibTeX
@article{Nakipoglu2026,
author = {Nakipoglu, Mustafa and Mahmoodi, Mahboobeh and Apu, Ehsanul Hoque and Shahabipour, Fahimeh and Emir Diltemiz, Sibel and Saha, Sanjib and Alem, Halima and Ashammakhi, Nureddin},
title = {Advances in 3D Bioprinting for Breast Cancer Modeling: Tumor Microenvironment, Metastasis, and Drug Screening},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.71734}
}
EUVIMED